Skip to main content

Frazier Life Sciences — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

46
Companies
$5.3B
Total invested
$117.7M
Avg. check
12
Industries
Biotechnology 20Health Care 14Therapeutics 11Medical 8Biopharma 7Pharmaceutical 6+6 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2546 of 46
35Pharma
November 2024

35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.

Biopharma · Montreal$53.0M Series C
Vima Therapeutics
March 2026

Vima Therapeutics operates as a biotechnology company.

Biotechnology · Cambridge$40.0M Series A
AirNexis Therapeutics
January 2026

AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions.

Biotechnology · Palo Alto$200.0M Series A
Diagonal Therapeutics
January 2026

Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.

Biopharma · Watertown$125.0M Series B
Braveheart Bio
November 2025

Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.

Biotechnology · San Francisco$185.0M Series A
Maze Therapeutics
September 2025

Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.

Biopharma · South San Francisco$150.0M Post Ipo Equity
Enlaza Therapeutics
September 2025

Enlaza Therapeutics is a biotechnology research company.

Biopharma · La Jolla$15.0M Series Unknown
Trevi Therapeutics
June 2025

Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.

Biotechnology · Sandy Hook$115.1M Post Ipo Equity
ORIC Pharmaceuticals
May 2025

ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.

Biopharma · South San Francisco$125.0M Post Ipo Equity
Attovia Therapeutics
April 2025

Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.

Biotechnology · San Carlos$90.0M Series C
Hillstar Bio
March 2025

Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.

Biotechnology · Boston$67.0M Series A
Alesta Therapeutics
January 2025

Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic.

Biotechnology · Leiden$67.0M Series A
GondolaBio
August 2024

GondolaBio researches, develops and manufactures pharmaceutical products.

Biotechnology · Palo Alto$300.0M Series Unknown
Halda Therapeutics
August 2024

Halda Therapeutics is a research-stage drug discovery company.

Biotechnology · New Haven$126.0M Series B
Scorpion Therapeutics
July 2024

Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.

Biotechnology · Boston$150.0M Series C
Bluejay Therapeutics
May 2024

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.

Biotechnology · San Mateo$182.0M Series C
Applied Therapeutics
February 2024

Applied Therapeutics uses drug-development approach to target molecules and pathways that has roles in fatal or debilitating diseases.

Biotechnology · New York$100.0M Post Ipo Equity
Sudo Biosciences
February 2024

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

Biopharma · Carmel$30.0M Series B
Lassen Therapeutics
December 2023

Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.

Biotechnology · San Diego$85.0M Series B
Radionetics Oncology
August 2023

Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics.

Health Care · California City$52.5M Series A
Krystal Biotech
May 2023

Krystal Biotech provide significant clinical benefit for patients suffering from rare debilitating disorders..

Biopharma · Pittsburgh$160.0M Post Ipo Equity

Where Frazier Life Sciences invests

Biotechnology20
Health Care14
Therapeutics11
Medical8
Biopharma7
Pharmaceutical6

About Frazier Life Sciences's portfolio

How many companies has Frazier Life Sciences invested in?

Frazier Life Sciences has invested in 46 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Frazier Life Sciences invest in?

Frazier Life Sciences's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 12 different industry categories.

What is Frazier Life Sciences's largest investment?

Among tracked funding rounds, GondolaBio received $300.0M in a Series Unknown round. Frazier Life Sciences's total known invested capital is $5.3B.

What is the average investment size for Frazier Life Sciences?

Frazier Life Sciences's average investment size is $117.7M across its portfolio of 46 companies.

What are Frazier Life Sciences's most recent investments?

Recent Frazier Life Sciences portfolio additions include 35Pharma, Vima Therapeutics, AirNexis Therapeutics, Diagonal Therapeutics, Braveheart Bio. These companies were founded in 2020 or later.

Reach the founders behind these 46 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →